Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model

Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model

Summary: In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroargi...

Full description

Bibliographic Details
Main Authors: Joseph C. McCarthy, MS, Mark Aronovitz, MS, Jennifer J. DuPont, PhD, Timothy D. Calamaras, PhD, Iris Z. Jaffe, MD, PhD, Robert M. Blanton, MD
Format: Article
Language:English
Published: Elsevier 2017-06-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X17300979

Similar Items

Similar Items